Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03919058
Other study ID # RST-MS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 13, 2019
Est. completion date April 30, 2021

Study information

Verified date August 2021
Source Hasselt University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the impact of reducing sitting time and increasing exercise time on cardiometabolic health in persons with Multiple Sclerosis.


Description:

To date, it is clear that sedentary behaviour is strongly related to an increased risk of type II diabetes, cardiovascular disease and premature mortality. People suffering from chronic disabilities appear to be particularly susceptible to a sedentary lifestyle and inactivity due to primary disease symptoms. To date, this is an important new research topic in Multiple Sclerosis (MS, ~2.3 million people worldwide, ~10-12.000 diagnosed in Belgium) treatment, since previous research reported a significantly higher prevalence of sedentary behaviour in persons with MS (PwMS) compared to healthy controls (HC). PwMS are reported to have a 40% lower daily step count compared to healthy inactive persons and tend to accumulate their sedentary time in longer bouts. As described above and similar to other chronic conditions, a sedentary lifestyle also makes PwMS more vulnerable to the accumulation of important cardiometabolic comorbidities that seem inactivity-related rather than a direct result of non-reversible tissue injury. Such comorbidities include impaired whole body glycaemic control, an abnormal blood lipid profile, an unhealthy body composition and hypertension. In this respect, it is important to note that corticosteroids, which are often used to treat MS patients pharmacologically, elevate fasting glucose and insulin concentrations and induce insulin resistance in HC therefore probably also increase several cardiometabolic risk factors in MS. Up to now, research in MS has been focused on structured exercise and its positive effects on functional parameters are well-known (e.g. improvements in cardiorespiratory fitness, muscle strength, balance, fatigue, cognition, quality of life and respiratory function). However, evidence is growing that sedentary time, independent of the (dis)practice of structured exercise, is an important independent health risk factor. Consequently, any strategy that also improves cardiometabolic health may help to further optimize rehabilitation in MS. Breaking up and reducing sedentary time with easy, daily activities such as household activities and other activities which increase light-intensity walking and standing, known as non-exercise physical activity (NEPA) may be such a strategy. NEPA has already been shown to significantly improve cardiometabolic risk markers in healthy, sedentary subjects, type II diabetes patients and obese adults and it involves lower intensity physical activities that are probably more feasible for PwMS. Moreover, with comparable activity workloads, reducing sitting time by NEPA of longer duration decreases insulin levels and fasting lipid levels more than performing one structured exercise bout of moderate intensity that is usually described in current activity guidelines. So far however, acute exercise bouts and NEPA effects on cardiometabolic health in this population have never been described. Therefore, the aim of this study is to investigate whether (1) cardiometabolic health (glycaemic control, blood lipids, inflammation markers and blood pressure) of persons with MS improves when sedentary time is reduced and (2) NEPA results in better cardiometabolic health parameters than (a shorter daily bout of) moderate-intensity exercise when workload of both activities is identical in this population.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date April 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Signed informed consent - Men and women =18 years old - Clinical diagnosis of MS (McDonald criteria) - Expanded Disability Status Score = 5 - Daily internet access Exclusion Criteria: - Reported participation in another biomedical trial which may have an effect on blood parameters one month before the pre-study examination or during the study - Blood donation in the past three months - Pregnancy or intention of becoming pregnant - Reported dietary habits: medically prescribed diet, slimming diet - Reported weight loss (>2kg) in the last three months prior to the screening - Alcohol use > 20 units per week (during the last 3 months) - Experimental drug use (during the last 3 months) - Medication changes (during the last month) - Medical conditions which make participation in the study not responsible: - Heart failure: New York Heart Association (NYHA) 3 or higher - Angina pectoris or signs of cardiac ischemia during exercise testing - Mental or physical disability - Based on historical information not able to walk for 3h per day and stand for 4h per day (e.g. intermittent claudication)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Baseline activity (control regime)
This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
Increased sitting time (sit regime)
Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
Non-exercise physical activity (sit less regime)
Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
Structured exercise (exercise regime)
One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.

Locations

Country Name City State
Belgium Hasselt University Diepenbeek Limburg

Sponsors (1)

Lead Sponsor Collaborator
Hasselt University

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Steps per day Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the control regime
Primary Sitting time Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the control regime
Primary Standing time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the control regime
Primary Stepping time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the control regime
Primary Concentration of glucose Blood analysis Day after the control regime
Primary Concentration of insulin Blood analysis Day after the control regime
Primary Concentration of total cholesterol Blood analysis Day after the control regime
Primary Concentration of high density lipoprotein cholesterol (HDL-cholesterol) Blood analysis Day after the control regime
Primary Concentration of low density lipoprotein cholesterol (LDL-cholesterol) Blood analysis Day after the control regime
Primary Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol) Blood analysis Day after the control regime
Primary Concentration of triglyceride Blood analysis Day after the control regime
Primary Concentration of apolipoprotein A1 (apo A1) Blood analysis Day after the control regime
Primary Concentration of apolipoprotein B (apo B) Blood analysis Day after the control regime
Primary Concentration of free fatty acids (FFA) Blood analysis Day after the control regime
Primary Concentration of C-reactive protein (CRP) Blood analysis Day after the control regime
Primary Concentration of interleukin 1 (IL-1) Blood analysis Day after the control regime
Primary Concentration of interleukin 6 (IL-6) Blood analysis Day after the control regime
Primary Steps per day Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit regime
Primary Sitting time Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Dag 1 to 4 of the Sit regime
Primary Standing time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit regime
Primary Stepping time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit regime
Primary Concentration of glucose Blood analysis Day after the Sit regime
Primary Concentration of insulin Blood analysis Day after the Sit regime
Primary Concentration of total cholesterol Blood analysis Day after the Sit regime
Primary Concentration of high density lipoprotein cholesterol (HDL-cholesterol) Blood analysis Day after the Sit regime
Primary Concentration of low density lipoprotein cholesterol (LDL-cholesterol) Blood analysis Day after the Sit regime
Primary Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol) Blood analysis Day after the Sit regime
Primary Concentration of triglyceride Blood analysis Day after the Sit regime
Primary Concentration of apolipoprotein A1 (apo A1) Blood analysis Day after the Sit regime
Primary Concentration of apolipoprotein B (apo B) Blood analysis Day after the Sit regime
Primary Concentration of free fatty acids (FFA) Blood analysis Day after the Sit regime
Primary Concentration of C-reactive protein (CRP) Blood analysis Day after the Sit regime
Primary Concentration of interleukin 1 (IL-1) Blood analysis Day after the Sit regime
Primary Concentration of interleukin 6 (IL-6) Blood analysis Day after the Sit regime
Primary Steps per day Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit Less regime
Primary Sitting time Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit Less regime
Primary Standing time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit Less regime
Primary Stepping time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Sit Less regime
Primary Concentration of glucose Blood analysis Day after the Sit Less regime
Primary Concentration of insulin Blood analysis Day after the Sit Less regime
Primary Concentration of total cholesterol Blood analysis Day after the Sit Less regime
Primary Concentration of high density lipoprotein cholesterol (HDL-cholesterol) Blood analysis Day after the Sit Less regime
Primary Concentration of low density lipoprotein cholesterol (LDL-cholesterol) Blood analysis Day after the Sit Less regime
Primary Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol) Blood analysis Day after the Sit Less regime
Primary Concentration of triglyceride Blood analysis Day after the Sit Less regime
Primary Concentration of apolipoprotein A1 (apo A1) Blood analysis Day after the Sit Less regime
Primary Concentration of apolipoprotein B (apo B) Blood analysis Day after the Sit Less regime
Primary Concentration of free fatty acids (FFA) Blood analysis Day after the Sit Less regime
Primary Concentration of C-reactive protein (CRP) Blood analysis Day after the Sit Less regime
Primary Concentration of interleukin 1 (IL-1) Blood analysis Day after the Sit Less regime
Primary Concentration of interleukin 6 (IL-6) Blood analysis Day after the Sit Less regime
Primary Steps per day Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Exercise regime
Primary Sitting time Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Exercise regime
Primary Standing time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Exercise regime
Primary Stepping time Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). Day 1 to 4 of the Exercise regime
Primary Concentration of glucose Blood analysis Day after the Exercise regime
Primary Concentration of insulin Blood analysis Day after the Exercise regime
Primary Concentration of total cholesterol Blood analysis Day after the Exercise regime
Primary Concentration of high density lipoprotein cholesterol (HDL-cholesterol) Blood analysis Day after the Exercise regime
Primary Concentration of low density lipoprotein cholesterol (LDL-cholesterol) Blood analysis Day after the Exercise regime
Primary Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol) Blood analysis Day after the Exercise regime
Primary Concentration of triglyceride Blood analysis Day after the Exercise regime
Primary Concentration of apolipoprotein A1 (apo A1) Blood analysis Day after the Exercise regime
Primary Concentration of apolipoprotein B (apo B) Blood analysis Day after the Exercise regime
Primary Concentration of free fatty acids (FFA) Blood analysis Day after the Exercise regime
Primary Concentration of C-reactive protein (CRP) Blood analysis Day after the Exercise regime
Primary Concentration of interleukin 1 (IL-1) Blood analysis Day after the Exercise regime
Primary Concentration of interleukin 6 (IL-6) Blood analysis Day after the Exercise regime
Secondary Blood pressure Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements. Day after the Control regime
Secondary Body weight Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg Day after the Control regime
Secondary Blood pressure Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements. Day after the Sit regime
Secondary Body weight Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg Day after the Sit regime
Secondary Blood pressure Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements. Day after the Sit Less regime
Secondary Body weight Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg Day after the Sit Less regime
Secondary Blood pressure Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements. Day after the Exercise regime
Secondary Body weight Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg Day after the Exercise regime
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4